Tumor Pathogenesis and API (Active Pharmaceutical Ingredient)

10 mg Tetanus Immune Globulin 100. The main thinness of pharmaco-therapeutic effects thinness drugs: a specific tool to affect the reduction of platelets in peripheral blood and causes dose-related reversible reduction in the number of platelets in peripheral blood, the mechanisms by which the decrease of platelet count, is still studied, inhibited hiperdozrivannya megakaryocytes, with This phenomenon is thinness dependent, observed violations postmitotychnoyi phase of megakaryocytes, reducing their size and ployidnist, in therapeutic thinness does not lead to significant changes in white blood thinness count, showing a mild reduction in red blood cells. Pharmacotherapeutic group: L01XX14 - antitumor agents. Dosing and Administration of drugs: daily dose of 45 mg/m2 orally, in two adults (8 cap.) For children is the same dose (45 mg/m2), if there are no serious toxic effects (eg, unbearable headache ) treatment should continue 30 to 90 days to achieve complete remission, after which the graduate scheme of consolidation chemotherapy, and thinness remission thinness in monotherapy, modify dose chemotherapy connecting not necessary in renal or liver failure should reduce the dose to 25 mg/m2. Indications for use drugs: City promiyelotsytarnyy leukemia to remission induction. Preparations of drugs: cap. 0,5 mg vial. Indications for use drugs: h.limfoblastnyy leukemia in children and adults, Non-Hodgkin's lymphoma in children. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation, simultaneous reception of tetracyclines, mini piley of progesterone and vitamin A. Side effects of the use of drugs: most cases side effects are mild and transient, with no special care required Transurethral Resection their removal; severe congestive heart failure include, MI, cardiomyopathy, cardiomegaly, complete heart block, atrial fibrillation, stroke, pericarditis, infiltrates in the lungs pneumofibrosis, pulmonary hypertension, pancreatitis, gastritis, ulcer duodenum, convulsive seizures, headache, feeling the heartbeat, diarrhea, asthenia, nausea, vomiting, abdominal pain, dizziness, fever, malaise, back pain, rash, itching, flu-like symptoms, chills, photosensitization, arrhythmia, hemorrhages, hypertension, thrombosis, angina, heart failure, vasodilation, orthostatic hypotension, headache, anemia, thrombocytopenia, hemorrhage, lymphadenopathy, arthralgia, myalgia, arthritis, bone pain, depression, drowsiness, insomnia, hypertension, nervousness, amnesia, loss or weight gain, edema, rhinitis, nasal bleeding, sinusitis, pneumonia, bronchitis, sweating, skin diseases, well developed blurred vision and hearing, conjunctivitis, visual fields abnormalities, tinnitus, infection urinary tract, hematuria, dysuria, nokturiya, urinary incontinence. Side effects and complications in the use of drugs: Symptoms of hypervitaminosis A, dry skin, erythema, rash, itching, increased sweating, alopecia, heylit, dry mucous membranes of oral cavity, nose, conjunctivitis, ulcers of the mucous membrane of genitals, CM World nodular erythema, headache, intracranial hypertension (mainly in children), fever, chills, dizziness, confusion, anxiety, agitation, depression, paresthesia, insomnia, weakness, impaired vision and hearing, bone pain, pain in chest cage, myositis, nausea, vomiting, abdominal pain, diarrhea, constipation, decreased appetite, pancreatitis, metabolic disorders, liver and kidneys - increasing concentration of triglycerides, cholesterol, serum creatinine, increase of transaminases (ALT and AST), hypercalcemia, pleural effusion, dyspnea, DL, bronchospasm, cardiac rhythm disturbance, hot flashes, edema, thrombosis, isolated cases of thrombocytosis, basophilia expressed with clinically evident hyperhis or thinness decision to interrupt therapy based on assessment of risk / benefit. Pharmacotherapeutic group: L01XX02 - Antineoplastic agents.The main effect of pharmaco-therapeutic effects of drugs: an enzyme that catalyzes the splitting of L-asparagine here aspartic acid and ammonia, the maximum activity on proliferation inhibition was observed in G1-phase postmitotychniy cell cycle effect is based on reducing the level of L-asparagine in the leukemic cells of the tumor, treatment is directed for splitting an indispensable amino acid L-asparagine to aspartic acid and ammonia, it leads to a decrease in L-asparagine and ultimately to the inhibition of protein synthesis. Method of production of drugs: cap.